Maze Therapeutics, Inc.

NASDAQ:MAZE

Biotechnology

Healthcare
$31.20 +0.74%

+$0.18 today

Market cap
$1.71B
Beta
2.26
P/E (TTM)
-11.0
EPS (TTM)
-$2.27
52W Low $9.83High $53.65

Volume 0.71M

Average 0.84M

MAZE Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Maze Therapeutics, Inc.NASDAQ: MAZE

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables growth accelerates

Q1 FY2026 accounts payables of $2.21M rose 282.0% year over year, ahead of the +159.9% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at -80.7% a year.

Context

  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +282.0% holds above the trailing-twelve-month pace of +159.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.21M+296.6% QoQ
Last fiscal yearDec 2025
-$27K-86.8% YoY
LTMMar 2026
$1.61M+159.9% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+282.0%——
1 year-86.8%——
3-year CAGR-80.7%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(27K) USD
Year-over-year change
+86.8%

Accounts Payables vs competitors

How MAZE compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +159.9% is the 3rd highest of 6, against a peer median of +151.1%.
  • Accounts payables amounts to 8.0% of revenue for MAZE, versus a peer median of 3.3%.
MAZE Competitors
Accounts Payables for MAZE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARDXArdelyx, Inc.LTM Mar 2026$14.47M USD+507.1%-21.1%3.4%
SEPNSepterna, Inc.LTM Sep 2026$3.07M USD+363.6%+56.4%3.2%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$2.72M USD+151.1%—0.4%
IVAInventiva S.A.FY2025€2.46M EUR—-11.4%54.8%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$1.8M USD+126.9%+33.5%—
MAZEMaze Therapeutics, Inc.LTM Mar 2026$1.61M USD+159.9%-80.7%8.0%
BIOABioAge Labs, Inc.LTM Mar 2026$933K USD-155.1%-7.4%9.0%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding MAZE) —+151.1%-7.4%3.3%

Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(114.94M)(100.42M)52.23M(131.12M)
Depreciation & Amortization3.82M4.09M3.3M2.4M
Deferred Income Tax0000
Stock-Based Compensation6.74M8.75M9.65M16.4M
Change in Working Capital(3.24M)(6.32M)(1.52M)(2.27M)
Accounts Receivables0000
Inventory0000
Accounts Payables(3.78M)399K(204K)(27K)
Other Working Capital541K(6.72M)(1.32M)(2.25M)
Other Non-Cash Items8.42M7.07M12.3M2.65M
Operating Cash Flow(99.2M)(86.83M)75.95M(111.94M)
Capital Expenditures(1.97M)(441K)(1.15M)(794K)
Acquisitions (Net)(1.2M)000
Purchases of Investments000(187.67M)
Sales of Investments00017.5M
Other Investing Activities0000
Investing Cash Flow(3.17M)(441K)(1.15M)(170.96M)
Debt Repayment016.18M24.48M0
Common Stock Issued1.73M209K68.37M275.84M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities000(500K)
Financing Cash Flow1.73M16.39M92.85M275.34M
Effect of Forex Changes0000
Net Change in Cash(100.65M)(70.88M)167.65M(7.57M)
Free Cash Flow(101.17M)(87.27M)74.81M(112.73M)

Maze Therapeutics, Inc.

NASDAQ:MAZE

Intrinsic Alpha fair value

Locked

Current Price

$31.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.